US › Healthcare

Charles River Laboratories (CRL)

US · Healthcare · Diagnostics & Research

$234.12+1.41%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$995.8M
Revenue YoY
+1.2%
Net profit
$-14.8M
Profit YoY
-158.3%
EPS
$2.06
EPS estimate
$1.95
Net margin
-1.5%

EPS came in at 2.06 against a street estimate of 1.95 — a beat of 5.6%.

Key statistics

Market cap
$11.30B
Forward P/E
20.9
P/B
3.81
Book value
$61.05
EPS (TTM)
$-3.72
52-week high
$242.73
52-week low
$144.26
50-day MA
$204.52
200-day MA
$187.21
Beta
1.38

Analyst view

Analysts rate Charles River Laboratories a hold (4 buy, 14 hold, 1 sell out of 19) with an average price target of $230.93.

Shareholding

Insiders
0.64%
Institutions
123.90%

Largest institutional holders

FundStake
Vanguard Group Inc12.22%
BlackRock Inc8.01%
FMR Inc7.18%
Vanguard Capital Management, LLC6.65%
Amvescap Plc.4.98%
Vanguard Portfolio Management, LLC4.76%
Harris Associates L.P.4.47%
Allspring Global Investments Holdings, LLC4.14%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Charles River Laboratories — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.